TJP1 and neoplasm: The SG3GL2 promoter is activated and leads to up-regulated expression of SG3GL2 to inhibit the expression of ZO-1/Occludin, to weaken the tight junction of endothelial cells, to increase permeability and to promote infiltration and migration of tumor cells (96).